CDK4 and cancer: For example, pharmacologic inhibitors (such as palbociclib and abemaciclib) of CDKs 4 and 6 (CDK4/6) have shown significant inhibitory activities against several solid tumors, inducing G1 cell cycle arrest, causing quiescence, apoptosis, or senescence in various cancer cells [10, 11, 12].